---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000013"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:00:47.473249+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics closes $5M second tranche of equity financing at 113% premium

## Summary
- Received second $5M tranche of $10M equity financing from JuvVentures (UK) Limited.
- Issued 500,000 shares at $10/share (113% premium to Jan 31 close of $4.70).
- Issued warrants for 755,728 shares at $18.00 per share.
- Funds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025.

## SEC filing metadata
- accession: 0001708599-25-000013
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000013/0001708599-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000013/ser-20250203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000013
- JSON: https://secwatch.observer/filing/0001708599-25-000013.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.